Goldman Sachs analyst Patrick Donnelly raised his price target on Exact Sciences (EXAS) to $75, citing the positive impact of its co-promotion agreement with Pfizer (PFE) on Cologuard announced last week. The analyst expects the transaction to be “fundamentally transformative” for Exact Sciences over the next 3-4 years in terms of its revenue growth potential, but sees the 50% upside reaction in the stock price as sufficient in capturing the upside. Donnelly keeps his Neutral rating on Exact Sciences.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.